-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Besifovir-Dipivoxil-maleate
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/441785-26-8.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 441785-26-8 |
| Description | Besifovir Dipivoxil maleate (LB80380 maleate) is an oral prodrug of LB80317. Besifovir Dipivoxil maleate (LB80380 maleate) is effective in hepatitis B virus (HBV) DNA suppression for both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients in preliminary studies. |
Product Information
| Synonyms | Besifovir Dipivoxil (maleate)|CS-0025391 |
| Molecular Weight | 527.508 |
| Molecular Formula | C26H38N5O12P |
| Purity | >97% |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid |
| Storage | Store at -20°C |
| PSA | 176.79000 |
| Target | HBV |
